DHA vs MOHAP License UAE (2025) – Full Guide + Verification
In the United Arab Emirates (UAE), all healthcare professionals must obtain a valid medical license from a recognized regulatory body before practicing medicine. This 2025 guide presents a detailed comparison of DHA vs MOHAP doctor licenses, focusing on jurisdictional authority, eligibility pathways, regulatory frameworks, and verification protocols. The two principal licensing authorities—Dubai Health Authority (DHA) and the Ministry of Health and Prevention (MOHAP)—govern distinct jurisdictions and operate under separate compliance systems.
Jurisdictional Authority and Licensing Portals
Understanding the inter-emirate licensing boundaries is critical for physicians pursuing multi-jurisdictional credentials or license portability. A DHA license is mandatory for practicing medicine in Dubai and is processed through the Sheryan Licensing System, which centralizes credential submission, primary source verification, and permit issuance. Conversely, a MOHAP license enables medical practice in Sharjah, Ajman, Umm Al Quwain, and Fujairah, managed via the MOHAP Professional Licensing Portal. Unlike DHA, which regulates healthcare practice within Dubai only, MOHAP oversees licensing for the Northern Emirates.
The following table outlines the structural differences between these two regulatory bodies:
| Criteria | DHA | MOHAP |
|---|---|---|
| Governing Emirate | Dubai | Northern Emirates (except Abu Dhabi) |
| Licensing Portal | Sheryan | MOHAP Portal |
| Eligibility Exams | Prometric UAE / Dubai | Prometric UAE |
DHA Licensing in Dubai: Requirements and Process
To legally practice medicine or any allied healthcare profession in Dubai, practitioners must obtain a valid DHA License issued by the Dubai Health Authority (DHA). This regulatory credential is mandatory for physicians, dentists, nurses, and allied health professionals. The licensing process begins with fulfilling Professional Qualification Requirements (PQR)—a framework defining the minimum academic degrees, clinical training, and work experience required for each healthcare category.
All credentials must undergo Primary Source Verification (PSV) via the DataFlow Group, which authenticates key documents including:
- Certificate of Experience
- Good Standing Certificate (GSC) from relevant medical councils
- Functional Fitness Certificate
- Emirates ID and passport copy
Applicants must complete the DHA Self-Assessment Tool, which automatically evaluates eligibility against PQR criteria. Qualified candidates receive an Eligibility Letter granting access to the DHA Licensing Exam, a Prometric-based test for roles that require clinical competency validation. Upon successful exam completion and final review, the practitioner is issued an official DHA License, authorizing medical practice exclusively within Dubai.
Verification, Compliance, and Federal Regulations
Verification of licensure through Sheryan (DHA) and the MOHAP Smart App is a legal requirement for employment validation, malpractice insurance coverage, and public safety. All licensed individuals are registered in the DHA Unified Medical Registry, a public database for real-time license verification. Employers, insurers, and patients can confirm licensure status, specialization, and compliance history using the Sheryan License Verification Portal, which reinforces transparency and regulatory assurance.
To maintain a DHA license, practitioners must complete periodic renewal, which requires submission of a current Good Standing Certificate, valid Emirates ID, evidence of Continuing Medical Education (CME) credit hours, and active malpractice insurance. These requirements ensure ongoing alignment with Federal Law No. 5 of 2019 on Medical Liability, a national legal framework that governs medical accountability, patient rights, and institutional compliance. Practicing without appropriate licensure constitutes a breach of this law, leading to penalties, invalidated medical records, and denied insurance claims.
Advancements in UAE Healthcare: MS Clinical Trials at ADSCC
Beyond licensing, the UAE is pioneering research and transforming healthcare through institutions like the Abu Dhabi Stem Cells Center (ADSCC). A milestone has been achieved in one of its ongoing clinical trials, the Extracorporeal Photopheresis (ECP) for Optimal Management of Multiple Sclerosis (PHOMS) study. The study at ADSCC, a PureHealth subsidiary, evaluates the safety and efficacy of using ECP to treat people with multiple sclerosis (MS).
As an immunomodulatory therapy, ECP in this study seeks to alleviate MS symptoms by rebalancing the immune system of the patient. The PHOMS trial involves the following protocols:
- Patients undergo a series of 28 ECP procedures spanning six months.
- Following the treatment, there is an additional period of six months for monitoring by the ADSCC Neurology team.
- The procedure involves treatment of a patient’s autologous leukocytes with a photoactivatable drug, followed by exposure to UVA light and subsequent reinfusion.
In 2022, ADSCC’s trial received approval from the Department of Health – Abu Dhabi (DOH) and is registered in the global clinical trials registry. The trial has already made significant strides, with participants reporting significant improvements in mobility, reduced imbalance-related issues, and clearer speech after six months of treatment.